Viking Therapeutics Set for Strong Advancement on Recent Obesity Dru...

Highlights,Viking Therapeutics reported significant weight loss results from its experimental obesity pill VK2735 during the ObesityWeek conference.,P...

A Share Adjustment in STERIS plc (NYSE:STE) Undertaken by US Bancorp...

Highlights,US Bancorp DE reduced its stake in STERIS plc by 17.8% in the third quarter, reflecting strategic adjustments in portfolio management.,STER...

Verona Pharma (NASDAQ:VRNA) Reports Q3 2024 Results with Promising O...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October sales outpace Q3 perform...

QIAGEN (NYSE:QGEN) Receives FDA Clearance for QIAstat-Dx Meningitis/...

Highlights:,QIAGEN secures fourth FDA clearance in 2024, enhancing its diagnostic offerings.,Rapid results in just one hour revolutionize the diagnosi...

Coronation Fund Managers Reduces Stake in Revvity, Inc.

Headlines,Coronation Fund Managers decreased its stake in Revvity, Inc. during the third quarter.,Major institutional investors are showing dynamic mo...

Elevance Health Attracts Increased Institutional Investment

Headlines,Coronation Fund Managers enhances Elevance Health stake,Notable hedge fund activity reflects confidence in Elevance Health,Elevance Health d...

What Does the Performance of The Cooper Companies Tell Us?

Highlights,The Cooper Companies experiences a significant increase in share price over the last year.,Long-term returns have not met market averages,...

Edwards Lifesciences (NYSE:EW) benefits from a rating upgrade by San...

Highlights,Edwards Lifesciences received an upgrade from "strong sell" to "hold" from Sanford C. Bernstein amid a challenging market environment.,The...

Eli Lilly's shares face a decline due to unmet quarterly profit esti...

Highlights,Eli Lilly reported third-quarter profits that fell short of Wall Street estimates, primarily due to higher manufacturing costs and a substa...

How Did BrainStorm Cell Therapeutics Regain Nasdaq Compliance?

Highlights,BrainStorm Cell Therapeutics announces compliance with Nasdaq's listing requirements.,The company specializes in autologous stem cell thera...

Vera Therapeutics (NASDAQ:VERA) receives a new price target of $64.0...

Highlights,Guggenheim has raised its price objective for Vera Therapeutics from $56 to $64, indicating potential upside for the stock.,The company spe...

BrainStorm Cell Therapeutics successfully restores compliance with N...

Highlights,BrainStorm Cell Therapeutics Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on The Na...

Brooklyn ImmunoTherapeutics: Pioneering Innovation in Cancer Treatme...

Headlines,Brooklyn ImmunoTherapeutics Gains Momentum,Innovative Treatments for Regenerative Medicine,Exploring New Horizons in Cancer Care,Brooklyn Im...

What Financial Challenges Does Evoke Pharma Face?

Highlights,Evoke Pharma Inc. focuses on developing treatments for gastroenterological disorders.,The company is approaching a potential milestone towa...

Analysts Maintain Positive Outlook on AbbVie Inc

Headlines,Analysts have a favorable view of AbbVie Inc.,Recent price targets reflect strong confidence in the company.,Multiple upgrades highlight Abb...

Global Cord Blood Gains Analyst Attention for Stem Cell Services

Headlines,Global Cord Blood Gains Analyst Attention,Key Services Offered by Global Cord Blood,Future Prospects of Global Cord Blood,Global Cord Blood,...

What Are the Implications of GlycoMimetics' Latest Move?

Highlights,GlycoMimetics enters into an acquisition agreement with Crescent Biopharma.,The combined entity will focus on innovative treatments for sol...

Novartis's Q3 net profit increase has resulted in a raised annual sa...

Highlights,Increased Annual Guidance,: Novartis AG revised its annual sales forecast, anticipating growth in low double-digits, reflecting strong perf...

Pfizer's Q3 earnings preview reveals strong growth potential for PFE...

Highlights,Strong Q3 Projections,: Pfizer anticipates an earnings per share (EPS) of $0.61 and revenue of $14.87 billion for Q3, showcasing significan...

TransMedics (TMDX) Reports Impressive Q3 2024 Financial Results

Highlights:,TransMedics achieves 64% revenue growth, reaching $108.8 million in Q3.,The company reports net income of $4.2 million, a significant turn...